Related Experiment Video
Updated: Jul 6, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Interleukin-7 in rheumatoid arthritis.
1The University of Leeds, Leeds Institute of Molecular Medicine, Section of Musculoskeletal Disease, St James's University Hospital, Leeds, LS9 7TF, UK.
Rheumatology (Oxford, England)
|March 22, 2008
Summary
Interleukin-7 (IL-7) is elevated in rheumatoid arthritis (RA) joints, potentially driving inflammation and bone destruction. Lowering IL-7 may offer a novel therapeutic strategy for RA patients.
Area of Science:
- Immunology
- Rheumatology
- Cell Biology
Background:
- Elevated levels of Interleukin-7 (IL-7) observed in the joints of rheumatoid arthritis (RA) patients, contrasting with lower levels in osteoarthritis (OA).
- Circulating IL-7 levels in RA are debated, but reduced levels may contribute to T cell dysfunction and systemic manifestations.
- IL-7 plays critical roles in human T cell, dendritic cell, and bone biology.
Purpose of the Study:
- To investigate the dual role of IL-7 in rheumatoid arthritis, differentiating between its local and systemic effects.
- To explore the potential of IL-7 as a therapeutic target for managing RA-associated inflammation and joint destruction.
Main Methods:
- Analysis of IL-7 levels in joint tissues and circulation of RA and OA patients.
- Review of existing literature on IL-7's functions in immune cells and bone metabolism.
- Examination of the regulatory pathways involving IL-7, IL-1beta, TNF-alpha, and osteoclastogenesis.
Main Results:
- High intra-articular IL-7 levels in RA, significantly higher than in OA.
- IL-7 in the joint promotes a cycle of inflammation by up-regulating TNF-alpha production and inducing osteoclastogenic cytokines.
- IL-7 links stromal cells with innate and adaptive immunity, potentially orchestrating chronic inflammation and bone destruction in RA.
Conclusions:
- Intra-articular IL-7 is implicated in perpetuating RA inflammation and driving bone destruction.
- IL-7's role in inducing osteoclast maturation via T cells is a key mechanism of joint damage.
- Targeting IL-7 presents a promising therapeutic avenue for rheumatoid arthritis.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...